Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar;10(3):1272-1275.
doi: 10.21037/jtd.2018.03.61.

Intratumoral heterogeneity of Notch1 expression in small cell lung cancer

Takaaki Ito  1
Affiliations
Editorial

Intratumoral heterogeneity of Notch1 expression in small cell lung cancer

Takaaki Ito. J Thorac Dis. 2018 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Heterogeneous expression of Notch1 in small cell lung cancer SCLC). (A) Hypothetical natural history of SLCL is depicted, focusing on Notch1 expression. Naïve SCLC cells prior to chemoradiotherapy are Notch1-negative, and show neuroendocrine differentiation. These cells show epithelial-mesenchymal transition (EMT), motility, and high proliferative potential. Furthermore, they are very sensitive to cytotoxic therapies. On the contrary, chemotherapy and radiotherapy can induce Notch expression that may be regulated by histone modification (18). Notch1-positive SCLC cells are non-neuroendocrine and lose some of their EMT characteristics. They reduce cell proliferation activity, but produce chemoresistance; (B) Notch1 expression in recurred SCLC tissue of an autopsy case of a patient who received repeated chemotherapy. The recurred tumor contains a few Notch1-positive cells. (Hemoatoxylin and eosin stain. Bar =50 µm).
See this image and copyright information in PMC

Comment on

References

    1. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018;15:81-94. 10.1038/nrclinonc.2017.166 - DOI - PubMed
    1. Gupta RG, Somer RA. Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution. Mol Cancer Res 2017;15:1127-37. 10.1158/1541-7786.MCR-17-0070 - DOI - PubMed
    1. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-34. 10.1038/nrc3261 - DOI - PubMed
    1. Bunn PA, Jr, Minna JD, Augustyn A, et al. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 2016;11:453-74. 10.1016/j.jtho.2016.01.012 - DOI - PMC - PubMed
    1. Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017;14:549-61. 10.1038/nrclinonc.2017.71 - DOI - PMC - PubMed

LinkOut - more resources